PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsrheumatoid arthritis
MeSH D001172 - rheumatoid arthritis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D001327:Autoimmune diseases
$
Success rate
D001168:Arthritis
$
Success rate
D012216:Rheumatic diseases
D001172: 
Rheumatoid arthritis
D005258:Felty syndrome
0 Companies
0 Drugs
Success rate
D012859:Sjogren's syndrome
0 Companies
0 Drugs
Success rate
D016706:Adult-onset still's disease
0 Companies
0 Drugs
Success rate
D056653:Rheumatoid vasculitis
0 Companies
0 Drugs
Success rate
D002205:Caplan syndrome
0 Companies
0 Drugs
Success rate
D012218:Rheumatoid nodule
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
A.H. Robins CompanyAspirin, Methocarbamol Robaxisal  1982-01-01   
AAIPharmaAzathioprine Azasan  1999-06-07   
Aspirin, Propoxyphene napsylate Darvon-n W/ Asa  1982-01-01   
Abbott BiotherapeuticsAdalimumab Trudexa  2003-09-01   
Aspirin, Hydrocodone Vicoprin  1983-09-14   
Ibuprofen Ibu  1989-12-18   
Ibuprofen Ibuprofen  1985-06-14   
AbbVieAdalimumab Humira  2002-12-31 $13,133 M Q2/23-Q1/24 
Upadacitinib Rinvoq 2030-12-01 2019-08-16 $4,376 M Q2/23-Q1/24 
Ibuprofen, Hydrocodone Vicoprofen  1997-09-23   
Cyclosporine Cyclosporine  2000-03-03   
Cyclosporine Gengraf  2000-05-12   
Cyclosporine Restasis Multidose 2024-08-27 2002-12-23   
Able LaboratoriesNaproxen Naproxen  2003-08-22   
Accord HealthcareMethotrexate Methotrexate  2007-04-30   
Hydroxychloroquine Hydroxychloroquine  2020-04-07   
ACIC PharmaceuticalsCelecoxib Celecoxib  2020-12-09   
Aet PharmaLeflunomide Leflunomide  2021-05-10   
Ajanta PharmaTofacitinib Tofacitinib  2021-06-01   
Naproxen, Esomeprazole strontium Naproxen Esomeprazole Magnesium  2022-10-06   
AkornDiclofenac Diclofenac  2008-04-17   
1
2
3
4
5
6
...
23
>
Clinical Trials
Historical Success Rate
Phase 1
64%
72/113
Phase 2
47%
61/130
Phase 3
75%
119/158
Approved: 63Overall Success rate: 23%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Abbott Biotherapeutics
AbbVie
1
2
3
4
5
6
...
16
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use